Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Agilent Technologies Inc. (NYSE: A) shares gained 3.37 percent to close at $50.98 a share Thursday. The stock traded between $50.75 and $53.47 on volume of 18.15 million shares traded. The company announced that it plans to separate into two publicly traded companies: one in life sciences, diagnostics and applied markets. Shares of Agilent Technologies have gained approximately 66.0 percent year-to-date.
Get more information on Agilent Technologies and free access to the in-depth equity report at:
Apogee Enterprises Inc. (NASDAQ: APOG) shares declined 1.35 percent to close at $29.10 a share Thursday. The stock traded between $27.25 and $29.23 on volume of 411,956 shares traded. The company reported revenues were $178.3 million for the second quarter of fiscal 2014, an increase of just 1.0 percent when compared to a year ago. Shares of Apogee Enterprises have gained approximately 21.0 percent year-to-date.
Get more information on Apogee Enterprises and free access to the in-depth equity report at:
CLARCOR Inc. (NYSE: CLC) shares declined 4.97 percent to close at $54.65 a share Thursday. The stock traded between $53.00 and $56.32 volume of 509,088 shares traded. The company reported diluted earnings per share of $0.57 for the third quarter of fiscal 2013, a decrease of 5.0 percent when compared to a year ago. Shares of CLARCOR have gained approximately 14.0 percent year-to-date.
Get more information on CLARCOR and free access to the in-depth equity report at:
ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) shares surged 14.06 percent to close at $36.27 a share Thursday. The stock traded between $33.15 and $36.91 on volume of 5.03 million shares traded. The company reported positive results from a recent study of its spinal muscular atrophy drug. Shares of ISIS Pharmaceuticals have gained nearly 250.0 percent year-to-date.
Get more information on ISIS Pharmaceuticals and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...